‘I worry deeply about bioterrorism’: Is Europe sufficiently prepared for another pandemic?
Poinews.com – As the specter of bioterrorism looms, experts are raising alarms about Europe’s readiness for a potential resurgence of infectious disease threats. The lingering effects of the pandemic have underscored the importance of resilient health systems, yet concerns persist about the continent’s ability to respond swiftly to a crisis triggered by man-made agents. Industry leaders, including Moderna’s CEO Stéphane Bancel, have emphasized the need for localized infrastructure and preparedness plans to mitigate vulnerabilities. “I worry deeply about bioterrorism,” Bancel recently stated, highlighting the urgency of securing Europe’s capacity to manufacture and distribute vaccines independently.
The Role of mRNA Technology in Pandemic Preparedness
Moderna’s mRNA platform has been pivotal in rapid vaccine development during the pandemic, but its potential extends beyond infectious diseases. Bancel acknowledged that the company’s post-pandemic strategy now includes a broader range of therapeutic applications, such as cancer treatments and genetic disorders. However, this diversification does not diminish the critical role mRNA technology plays in countering both natural and engineered health threats. “Our mRNA-based solutions can be adapted to target pathogens with high precision, which is essential in scenarios like bioterrorism where time is a crucial factor,” he explained.
Despite its global reputation, Europe remains heavily reliant on international suppliers for vaccine production. Moderna’s efforts to establish local manufacturing facilities in the EU have been a key focus, yet challenges persist. The absence of a robust domestic mRNA infrastructure means that in the event of a bioterrorist attack, Europe may face delays in scaling up production. This gap has prompted calls for increased investment in biotechnology research and development, as well as public-private partnerships to ensure supply chain resilience.
Global Competitors and the Race for Innovation
Moderna is not the only player in the mRNA vaccine arena. Companies like BioNTech have also demonstrated the transformative power of this technology, but their recent decisions have raised questions about Europe’s long-term preparedness. In 2026, BioNTech announced the closure of its German production sites, shifting operations entirely to Pfizer’s U.S. facilities. This move has left Europe without a major mRNA manufacturing hub, a situation that could be exploited in a bioterrorism scenario. “The pandemic showed us how vital it is to have localized capabilities,” Bancel said, stressing that the continent must act quickly to avoid being caught off guard.
Meanwhile, other firms like Sana Biotechnology and Kailera Therapeutics have made strides in biotech innovation, with Kailera securing significant funding in early 2026. These developments highlight a growing global competition in vaccine development, but Europe’s strategic position remains precarious. Without a cohesive plan to integrate these advancements into national preparedness frameworks, the risk of a bioterrorism-induced health crisis looms larger than ever. “I worry deeply about bioterrorism because it could trigger a response that is both faster and more targeted than natural pandemics,” Bancel added.
Recent events have also shown how quickly global health dynamics can shift. The successful deployment of vaccines during the pandemic was a triumph, but it also exposed weaknesses in Europe’s infrastructure. As Parabilis Medicines raised $670 million on June 10, 2026, to advance its therapies, the competition for funding and innovation has intensified. This progress, however, must be matched by a commitment to strengthening Europe’s ability to respond to both medical and biological threats. “The pandemic taught us that agility is key, but we need to build systems that can sustain this agility over the long term,” Bancel noted.
Looking ahead, the conversation around bioterrorism is becoming more urgent as new technologies emerge. The ability to rapidly develop and deploy vaccines could be a game-changer in neutralizing man-made pathogens, but it requires strategic foresight and investment. Europe’s leaders are now faced with the challenge of ensuring that the continent’s biotech sector is not only competitive but also prepared to handle the unique demands of bioterrorism. “I worry deeply about bioterrorism because it could test our systems in ways we haven’t yet imagined,” Bancel concluded, urging a renewed focus on preparedness.
